AZD0233 / AstraZeneca - LARVOL DELTA

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants. (clinicaltrials.gov) - P1 | N=88 | Suspended | Sponsor: AstraZeneca | Recruiting ➔ Suspended

Trial suspension • Cardiomyopathy • Cardiovascular

AZD0233: An oral CX3CR1 antagonist in development for the treatment of cardiovascular disease (ACS-Fall 2025) - "Cardiac CX3CR1/CX3CL1 expression is elevated in humans with heart failure and a CX3CR1 antagonist has the potential to improve cardiac function in heart failure patients via immunomodulation of the CX3CR1/CX3CL1 axis.AZD0233 belongs to a new small molecule CX3CR1 antagonist series that have improved physicochemical properties, metabolic stability, secondary pharmacology, toxicity profile and lower CYP inhibition compared to previous CX3CR1 small molecule antagonists explored.When tested in a mouse model of dilated cardiomyopathy, AZD0233 demonstrated improved cardiac function, reduced macrophages and fibrotic scar. The compound has been well tolerated in animal studies and is currently in SAD/MAD Phase I clinical studies.The hit to lead identification and the optimisation of lead to clinical candidate will be presented as well as preclinical data and our current understanding of mode of action for AZD0233."

Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • CX3CL1 • CX3CR1